06/09/2026
"This study suggests that GLP-1 RAs may offer protective benefits beyond glycemic and weight control, potentially improving survival and recurrence risk in some female patients with breast cancer." Read more...
This cohort study of more than 800 000 patients with breast cancer evaluates the association between glucagon-like peptide-1 receptor agonist use and 10-year mortality and recurrence-free survival.